Skip to content

Trimas TRS Convertible Preferred Stock Outstanding Shares

Convertible Preferred Stock Outstanding Shares at other companies

West Pharmaceutical Services logo
West Pharmaceutical ServicesWST

Other financials

Income statement

See full
Revenue$168.3M+10.4%
Gross profit$36.9M+12.3%
Operating income$6.9M-3.6%
Net income$800.8M+6,348%
EPS (diluted)$21.40+7,033%

Balance sheet

See full
Cash & equivalents$1.3B+3,904%
Total debt$439.9M-9.2%
Total equity$1.4B+111%
Total assets$2.3B+64.8%

Cash flow

See full
Operating cash flow-$19.4M-311%
CapEx$5.2M-59.7%
Free cash flow-$24.6M-556%

Valuation

See full
Market cap$1.56B+41.9%

Profitability

See full
Gross margin-0.1%-2.1pp
Operating margin8%-1.0pp
Net margin137.3%+132pp
FCF margin7.3%+3.1pp

Returns & leverage

See full
Return on equity85.1%+80.4pp
Debt / equity0.3×-0.4×
Current ratio4.9×+2.0×

Where this comes from

Reported directly by Trimas in its filing.

Tagged under the XBRL concept us-gaap:PreferredStockSharesOutstanding.

The official record: Trimas’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Questions, answered.

What is Trimas's convertible preferred stock outstanding shares?
Trimas (TRS) reported convertible preferred stock outstanding shares of 0 in Q1 2026.
What does convertible preferred stock outstanding shares mean?
This represents the total number of preferred equity shares that can be converted into common stock at the holder's option. It is a key indicator of potential future dilution for common shareholders. Investors track this to understand the capital structure and the impact of potential equity conversion on earnings per share.